Stockscreener 앱 받기
1.25
13.64%
0.15
전일 마감가:
$1.10
열려 있는:
$1.09
하루 거래량:
1.77M
Relative Volume:
1.96
시가총액:
$87.32M
수익:
$20.76M
순이익/손실:
$-132.49M
주가수익비율:
-0.4682
EPS:
-2.67
순현금흐름:
$-108.55M
1주 성능:
+3.31%
1개월 성능:
-40.19%
6개월 성능:
-80.50%
1년 성능:
-81.80%
1일 변동 폭
$1.09
$1.30
1주일 범위
$1.09
$1.315
52주 변동 폭
$1.085
$7.66
C 4 Therapeutics Inc Stock (CCCC) Company Profile
명칭
C 4 Therapeutics Inc
전화
(617) 231-0700
주소
490 ARSENAL WAY, WATERTOWN
CCCC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
1.25 | 87.32M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Equal-Weight |
| 2024-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-12-13 | 업그레이드 | Stifel | Hold → Buy |
| 2023-02-24 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-04-28 | 개시 | Credit Suisse | Underperform |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-10 | 개시 | JP Morgan | Overweight |
| 2022-02-11 | 재개 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-11-23 | 개시 | BofA Securities | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
| 2021-09-30 | 개시 | Stifel | Hold |
| 2021-06-04 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-27 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-27 | 개시 | Jefferies | Buy |
모두보기
C 4 Therapeutics Inc 주식(CCCC)의 최신 뉴스
Investors Don't See Light At End Of C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Tunnel And Push Stock Down 40% - simplywall.st
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - TradingView
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Announces Board Member Retirement - Investing.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics stock hits 52-week low at $1.38 By Investing.com - Investing.com Australia
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Expands Team: Strategic RSU Grants Worth 8,400 Shares to Attract Top Talent - Stock Titan
C4 Therapeutics stock hits 52-week low at $1.38 - Investing.com
Terns Pharmaceuticals Reports Inducement Grant To New Employees Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
C4 Therapeutics stock plunges to 52-week low of $1.95 By Investing.com - Investing.com South Africa
C4 Therapeutics stock plunges to 52-week low of $1.95 - Investing.com
Summit Therapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4) - Marketscreener.com
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer - GlobeNewswire
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C 4 Therapeutics Inc (CCCC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
C 4 Therapeutics Inc 주식 (CCCC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Boyle Scott N | Chief Business Officer |
Feb 14 '25 |
Sale |
3.15 |
490 |
1,544 |
110,842 |
2.51%
자본화:
|
볼륨(24시간):